The identification of a chlorinated MDMA

Journal of Analytical Toxicology

Volumn 29, Issue 5, 2005, Pages 353-358

  Maresova, V ^a   Hampl, J ^a   Chundela, Z ^b   Zrcek, F ^c   Polasek, M ^d   Chadt, J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c Institute of Criminalistics   (Czech Republic)

^d J HEYROVSKÝ INSTITUTE OF PHYSICAL CHEMISTRY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CANNABIS; COCAINE; ILLICIT DRUG; INFUSION FLUID;

ADULT; ALCOHOLIC BEVERAGE; CASE REPORT; CHEMICAL STRUCTURE; CHLORINATION; CLINICAL FEATURE; CONFERENCE PAPER; DRUG ABUSE; ELECTROSPRAY; GAS CHROMATOGRAPHY; HUMAN; HYPOVENTILATION; LIQUID LIQUID EXTRACTION; MALE; MASS SPECTROMETRY; THIN LAYER CHROMATOGRAPHY; TOXICITY TESTING; URINALYSIS;

CANNABIS;

EID: 23944507282     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/29.5.353     Document Type: Conference Paper

References (42)

1. G. Battaglia, B.P. Brooks, C. Kulsakdinum, and E.B. De Souza. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur. J. Pharmacol. 149: 159-163 (1988).
2. G. Ricaurte, L.E. De Lanney, I. Irwin, and J.W. Lagston. Toxic effects of MDMA on central serotogenic neurons in the primate: importance of route and frequency of drug administration. Brain Res. 446: 165-168 (1988).
3. J.A. Henry, K.J. Jeffreys, and S. Dawling. Toxicity and death from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 340: 384-387 (1992).
4. A.R. Green, A.J. Cross, and G.M. Goodwin. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacol. 119: 247-260 (1995).
5. R. de la Torre, M. Farre, J. Ortuno, M. Mas, R. Brenneisen, P.M. Roset, J. Segura, and J. Cami. Non-linear pharmacokinetics of MDMA ("ecstasy" ) in humans. Br. J. Clin. Pharmacol. 49: 104-109 (2000).
6. J. Cami, M. Farre, M. Mas, P.M. Roset, S. Poudevida, A. Mas, L. San, and R. de la Torre. Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects. J. Clin. Psychopharmacol. 20: 455-466 (2000).
7. J. Morland. Toxicity of drug abuse-amphetamine designer drugs (ecstasy): mental effects and cosequences of single dose use. Toxicol. Lett. 112-113: 147-152 (2000).
8. C. Hernandes-Lopez, M. Farre, P.N. Roset, E. Menoyo, N. Pizzaro, J. Ortuno, M. Torrens, J. Cami, and R. de la Torre. 3,4- Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J. Pharmacol. Exp. Ther. 300: 236-244 (2002).
9. J. Obrocki, A. Schmoldt, R. Buchert, B. Andersen, K. Petersen, and R. Thomasius. Specific neurotoxicity of chronic use of ecstasy. Toxicol. Lett. 127: 285-297 (2002).
10. A.R. Green, A.O. Mechan, J.M. Elliott, E. O'Shea, and M.I. Colado. The pharmacology and clinical pharmacology of 3,4-methylendioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 55: 463-508 (2003).
11. C. Back-Madruga, K.B. Boone, L. Chang, C.S. Grob, A. Lee, H. Nations, and R.E. Poland. Neuropsychological effects of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) in recreational users. Clin. Neuropsychol. 17: 446-459 (2003).
12. M.E. Liechti. "Ecstasy" (MDMA): pharmacology, toxicology, and management of intoxication. Dtsch. Med. Wochensschr. 128: 1361-1366 (2003).
13. F. Schifano. A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities. Psychopharmacology (Berl). 173: 242-248 (2004).
14. M.M. Patel, D.W. Wright, J.J. Ratcliff, and M.A. Miller. Shedding new light on the "safe" club drug: methylenedioxymethamphetamine (ecstasy)-related fatalities. Acad. Emerg. Med. 44: 208-210 (2004).
15. R. de la Torre, M. Farre, P.N. Roset, N. Pizarro, S. Abadanes, M. Segura, J. Segura, and J. Cami. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther. Drug. Monit. 26: 137-144 (2004).
16. T.J. Monks, D.C. Jones, F. Bai, and S.S. Lau. The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity. Ther. Drug. Monit. 26: 132-136 (2004).
17. H.J. Helmlin, K. Bracher, D. Bourquin, D. Vonlanthen, and R. Brenneisen. Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS. J. Anal. Toxicol. 20: 432-440 (1996).
18. H.H. Maurer. On the metabolism and the toxicological analysis of methylenedioxyphenylalkylamine designer drugs by gas chromatography-mass spectrometry. Ther. Drug. Monit. 18: 465-470 (1996).
19. T. Kraemer and H.H. Maurer. Determination of amhetamine, methamphetamine and amphetamine-derived designer drugs or medicaments in blood and urine. Review. J. Chromatogr. B 713: 163-187 (1998).
20. H.H. Maurer, J. Bickelboeller-Friedrich, T. Kraemer, and F.T. Peters. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ("Ecstasy"). Toxicol. Lett. 112-113: 133-142 (2000).
21. T. Kraemer and H.H. Maurer. Toxicokinetics of amphetamines: metabolism and toxicokinetics data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. Ther. Drug Monit. 24: 277-289 (2002).
22. F.T. Peters, S. Schaefer, R.F. Staack, T. Kraemer, and H.H. Maurer. Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood by gas chromatography-mass spectrometry. J. Mass Spectrom. 38: 659-676 (2003).
23. H.H. Maurer, T. Kraemer, D. Springer, and R.F. Staack. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (Ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther. Drug. Monit. 26: 127-131 (2004).
24. http://www.erowid.org/library/books_online/pihkal/pihkal109. shtml.
25. http://www.links.net/drugz/ex/synthesis.html.
26. http://www.totse.com/en/drugs/psychedelics/synth_no.html.
27. http://www.thedea.org/synthesis.html
28. M. Praisler, I. Dirinck, J.F. Van Bocxlaer, A.P. De Leenheer, and D.L. Messart. Computer-aided screening for hallucinogenic and stimulant amphetamines with gas chromatography-Fourier transform infrared spectroscopy (GC-FTIR). J. Anal. Toxicol. 25: 45-56 (2001).
29. http://www.erowid.org/chemicals/.
30. P.R. Stout, C.K. Horn, and K.L. Klette. Rapid simultaneous determination of amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine, 3,4-methylenedioxymethamphetamine and 3,4-methylenedioxyethylamphetamine in urine by solid phase extraction and GC-MS; a method optimized for high-volume laboratories. J. Anal. Toxicol. 26: 253-261 (2002).
31. F.T. Peters, N. Samyn, M. Wahl, T. Kraemer, G. De Boeck, and H.H. Maurer. Concentrations and ratios of amphetamine, methamphetamine, MDA, MDMA, and MDEA enetiomers determined in plasma samples from clinical toxicolgy and driving under influence of drugs cases by GC-NICI-MS. J. Anal. Toxicol. 27: 552-559 (2003).
32. J.C. Kraner, D.J. McCoy, M.A. Evans, L.E. Evans, and B.J. Sweeney. Fatalities caused by the MDMA-related drug paramethoxyamphetamine (PMA). J. Anal. Toxicol. 25: 645-648 (2001).
33. T.L Martin. Three cases of fatal paramethoxyamphetamine overdose. J. Anal. Toxicol. 25: 649-651 (2001).
34. R. Dams, E.A. De Letter, K.A. Mortier, J.A. Cordonnier, W.E. Lambert, M.H. Piette, S. Van Calenbergh, and A.P. De Leenheer. Fatality due to combined use of the designer drugs MDMA and PMA. A distribution study. J. Anal. Toxicol. 27: 318-322 (2003).
35. D. De Boer, M.J. Gizjels, I.J. Brosman, and R.A. Maes. More data about the new psychoactive drug 2C-B. J. Anal. Toxicol. 23: 227-228 (1999).
36. T. Decaestecker, E. De Letter, K. Clauwaert, M.P. Bouche, W. Lambert, J. Van Bosxlaer, M. Piette, E. Van den Eeckhout, C. Van Peteghem, and A. De Leenheer. Fatal 4-MTA intoxication: development of a liquid chromatographic- tandem mass spectrometric assay for multiple matrices. J. Anal. Toxicol. 25: 705-710 (2001).
37. T. Kanamori, H. Inoue, Y. Iwata, Y. Ohmae, and T. Kishi. In vivo metabolism of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in the rat: identification of urinary metabolites. J. Anal. Toxicol. 26: 61-66 (2002).
38. W. Dimpfel, M. Spuler, and D.E. Nichols. Hallucinogenic and stimulatory amphetamine derivatives: fingerprinting DOM, DOI, DOB, MDMA, and MBDB by spectral analysis of brain fields potentials in the freely moving rat (Tele-Stereo-EEG). Psychopharmacology 98: 297-303 (1989).
39. M. Donike. Acylierung mit bis (acylamiden)-N-methyl-bis- (trifluoracetamid) und bis-(trifluoracetamid), zwei neue reagenzien zur trifluoracetylierung. J. Chromatogr. 78: 273-279 (1973).
40. H.H. Maurer, A. Weber, and K. Pfleger. Mass Spectra and GC data of Drugs, Poisons, Pesticides, Pollutants and their metabolites. 1-4. VCH Verlagsgesellschaft, Weinheim, Germany, 1992, part 4, p 139.
41. L.A. King and A.J. Poortman van der-Meer. New synthetic drugs in the European Union. Sci. Justice 41: 200-202 (2001).
42. R.J. Lewis, D. Reed, A.C. Service, and A.M. Langford. The identification of 2-chloro-4,5-methylenedioxymethylamphetamine in an illicit drug seizure. J. Forensic Sci. 45: 1119-1125 (2000).